| Literature DB >> 27380996 |
Ritika Dutta1, Bruce Tiu1, Kathleen M Sakamoto2.
Abstract
CREB binding protein (CBP) and p300 are critical regulators of hematopoiesis through both their transcriptional coactivator and acetyltransferase activities. Loss or mutation of CBP/p300 results in hematologic deficiencies in proliferation and differentiation as well as disruption of hematopoietic stem cell renewal and the microenvironment. Aberrant lysine acetylation mediated by CBP/p300 has recently been implicated in the genesis of multiple hematologic cancers. Understanding the effects of disrupting the acetyltransferase activity of CBP/p300 could pave the way for new therapeutic approaches to treat patients with these diseases.Entities:
Keywords: CBP; CREB-binding protein; Hematologic malignancies; Lysine acetyltransferase activity; Targeted therapy; p300
Mesh：
Substances：
Year: 2016 PMID： 27380996 DOI： 10.1016/j.ymgme.2016.06.013
Source DB: PubMed Journal: Mol Genet Metab ISSN： 1096-7192 Impact factor: 4.797